retatrutide clinical trial results ⭐️topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating #retatrutide, an investigational GIP / GLP-1 / glucagon triple hormone receptor agonist, in adults with obesity or “overweight” VisualAbstract: Retatrutide reduces body weight

Patient Results Clinical studies and our own patient records show real success with this approach

2010;22(6):664-e203

Our risk stratified UM option includes additional clinical rigor such as the submission of chart notes and step therapy prior to reauthorizing weight loss treatment with a GLP-1 drug

Stopping Wegovy may cause weight regain, so ongoing healthy habits and medical supervision are essential for sustaining weight loss and overall health

The addition of GIP receptor activation in Retatrutide appears to improve tolerability rather than worsen it, which is consistent with what was observed in the shift from Semaglutide to Tirzepatide

Our products have been tested by an independent laboratory